Abbott Laboratories (ABT) Cash from Financing Activities (2009 - 2026)

Abbott Laboratories has reported Cash from Financing Activities for 18 years, with the latest figure at -$3.5 billion in Q2 2026.

• Quarterly Cash from Financing Activities fell 220.69% year-over-year to -$3.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $10.6 billion (up 261.45% YoY) and the FY2025 annual result came in at -$6.3 billion, down 16.75% from the prior year.
• Cash from Financing Activities fell to -$3.5 billion in Q2 2026 per ABT's latest filing, from $17.3 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $17.3 billion in Q1 2026 and troughed at -$3.8 billion in Q1 2022.
• A 5-year average of -$702.5 million and a median of -$1.5 billion in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities tumbled 295.35% in 2022, then surged 942.48% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$1.5 billion in 2022, then tumbled by 40.84% to -$2.1 billion in 2023, then rose by 9.31% to -$1.9 billion in 2024, then increased by 24.93% to -$1.4 billion in 2025, then sank by 151.83% to -$3.5 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$3.5 billion, $17.3 billion, and -$1.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.